FK 506 'rescue' immunosuppression for obliterative bronchiolitis after lung transplantation

Chest

Volumn 112, Issue 5, 1997, Pages 1175-1179

  Ross, David J ^a   Lewis, Michael Ian ^a   Kramer, Michelle ^a   Vo, Ashley ^a   Kass, Robert M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS;

ARTICLE; BRONCHIOLITIS; CHILD; CLINICAL ARTICLE; FORCED EXPIRATORY VOLUME; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; SPIROMETRY; SURVIVAL;

EID: 0030722049     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.112.5.1175     Document Type: Article

References (18)

1. Duncan S, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991; 10:638-46
2. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis: impact after isolated lung transplantation. Am Rev Respir Dis 1993; 147:1017-23
3. Keller CA, Cagle PT, Brown RW, et al. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest 1995; 107:973-80
4. International Society for Heart and Lung Transplantation. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993; 12:713-16
5. Griffith BP, Hardesty RL, Armitage JM, et al. A decade of lung transplantation. Ann Surg 1993; 218:310-20
6. The European FK 506 Multicentre Liver Study Group. Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK 506-based immunosuppression. Transplant Proc 1994; 26:3260-63
7. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK 506 immunosuppressive therapy - a clinicopathologic study of 96 patients. Transplantation 1991; 53:1056-62
8. American Thoracic Society. Standardization of spirometry - 1987 update. Am Rev Respir Dis 1987; 136:1299-307
9. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest 1984; 86:824-29
10. Yousem S, Paradis IK, Dauber J, et al. Efficacy of transbronchial biopsy in the diagnosis of bronchiolitis obliterans in heart-lung transplant recipients. Transplantation 1989; 47:893-95
11. Knoop C, Antoine M, Vachiery JL, et al. FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases. Transplant Proc 1994; 26:3240-41
12. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60:580-85
13. Nathan SD, Ross DJ, Belman MJ, et al. Bronchiolitis obliterans in single-lung transplant recipients. Chest 1995; 107: 967-72
14. Kesten S, Rajagopalan N, Maurer J. Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation. Transplantation 1996; 61:427-30
15. Meiser BM, Fuchs A, Schulze C, et al. FK 506 is superior to OKT3 for rescue therapy in cases of persistent rejection after intrathoracic transplantation. Dallas: American Society of Transplant Physicians 15th Annual Meeting, 1996; A254
16. Millis JM, Cronin DC, Newell KA, et al. Tacrolimus treatment of steroid resistant rejection provides economic advantages compared to OKT3 therapy. Dallas: American Society of Transplant Physicians 15th Annual Meeting, 1996; A128
17. 1995 Drug Pharmaceutical Red Book
18. Nair RV, Huang X, Morris RE, et al. Rapamycin but not leflunomide directly inhibits proliferation of human adult lung fibroblasts in response to growth factor stimuli. Dallas: American Society of Transplant Physicians 15th Annual Meeting, 1996; A142